Single Cell Genome Sequencing Market To Reach $7.55 Billion By 2030

Single Cell Genome Sequencing Market Growth & Trends

The global single cell genome sequencing market size is anticipated to reach USD 7.55 billion by 2030, according to a new report by Grand View Research Inc. The market is projected to grow at a CAGR of 16.1% from 2023 to 2030. Factor such as the increasing prevalence of chronic diseases like cancer, diabetes, and arthritis; advanced technology coupled with the latest collaborative efforts; increased investments in R&D; and rising geriatric population are anticipated to drive the market growth over the forecast period.

Active participation and contribution of market players toward product upgradation play an important role in the growth of the market. Increasing number of collaborations and strategic alliances between companies are fostering the development of a collaborative portfolio in the system. Moreover, the emergence of next-generation sequencing (NGS) has helped the market gain tremendous traction over the past few years. Earlier, single-cell genome sequencing market was dominated by PCR and microarray technologies. However, qPCR and NGS are increasingly emerging as the preferred technologies.

Furthermore, the rising number of single-cell genome sequencing centers & associated facilities worldwide is fostering growth prospects. The main objective of such entities is to develop novel single-cell genome sequencing-based applications and methods. These centers are also playing a major role in introducing advanced tools & instruments for scientific communities of various regions. In addition, public-private collaborations among governments, companies, and research institutions related to space are expected to promote more research initiatives. Various funding grants by NIH and private players such as Mission Bio are escalating the growth of the market.

 Request a free sample copy or view report summary: Single Cell Genome Sequencing Market Report

Single Cell Genome Sequencing Market Report Highlights

• Based on product type, the instruments segment dominated the market in 2022, with a revenue share of 57.43%. This domination can be largely attributed to the increased development and adoption of technologically advanced instruments

• Based on technology, PCR dominated the market in 2022, with a revenue share of 27.77%. Due to heavy investments in R&D, PCR is a widely recognized technology in the field of genome sequencing, highly coveted by market leaders and research institutes

• Based on workflow, the genomic analysis segment dominated the market in 2022, with a revenue share of 69.08%. This segment is also forecasted to have the fastest CAGR. This dominance can be attributed to the recent surge in funding for research and development capabilities and the widespread adoption of genomic analysis products

• Based on disease area, the cancer segment dominated the market in 2022 with a market share of 34.95%. The increasing prevalence of prostate, colorectal, and breast cancer is projected to generate lucrative opportunities for market growth.

• Based on application, the circulating tumor cells (CTCs) segment dominated the market in 2022, with a revenue share of 28.45%. This is due to the growing clinical application of CTCs as biomarkers for cancer detection

• Based on region, North America dominated the market in 2022 with a revenue share of 46.38%. owing to the extensive research and development activities, and the presence of a significant number of regional players. Asia Pacific region is anticipated to witness the fastest CAGR of 17.4% due to the rising geriatric population, leading to an increase in patients suffering from chronic diseases

Single Cell Genome Sequencing Market Segmentation

Grand View Research has segmented the global single cell genome sequencing market based on product type, technology, workflow, disease area, application, end-use, and region:

Single Cell Genome Sequencing Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents

Single Cell Genome Sequencing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• NGS

• PCR

• qPCR

• Microarray

• MDA

Single Cell Genome Sequencing Workflow Outlook (Revenue, USD Million, 2018 - 2030)

• Genomic Analysis

• Single Cell Isolation

• Sample Preparation

Single Cell Genome Sequencing Disease Area Outlook (Revenue, USD Million, 2018 - 2030)

• Cancer

• Immunology

• Prenatal Diagnosis

• Neurobiology

• Microbiology

• Others

Single Cell Genome Sequencing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Circulating Cells

• Cell Differentiation/Reprogramming

• Genomic Variation

• Subpopulation Characterization

• Others

Single Cell Genome Sequencing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic & Research Laboratories

• Biotechnology & Biopharmaceutical Companies

• Clinics

• Others

Single Cell Genome Sequencing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Single Cell Genome Sequencing Market

• Bio-Rad Laboratories

• 10x Genomics

• Novogene

• Fluidigm

• BGI

• Illumina, Inc.

• Oxford Nanopore Technologies

• Pacific Biosciences

• Thermo Fisher Scientific, Inc.

• QIAGEN

• F. Hoffmann-La-Roche Ltd.